Ronald Bailey from the February 2003 issue
(Page 2 of 4)
All these companies hope to cure the memory deficits that some 30 million baby boomers will suffer as they age. If these compounds can fix deficient memories, it is likely that they can enhance normal memories as well. Tsien points out that a century ago the encroaching senility of Alzheimer's disease might have been considered part of the "normal" progression of aging. "So it depends on how you define normal," he says. "Today we know that most people have less good memories after age 40, and I don't believe that's a normal process."
And so we face the prospect of pills to improve our mood, our memory, our intelligence, and perhaps more. Why would anyone object to that?
Eight objections to such enhancements recur in neuroethicists' arguments. None of them is really convincing.
Fukuyama falls into this same error when he suggests that even if there is some biological basis for their condition, people with ADHD "clearly ...can do things that would affect their final degree of attentiveness or hyperactivity. Training, character, determination, and environment more generally would all play important roles." So can Ritalin, and much more expeditiously, too. "What is the difference between Ritalin and the Kaplan SAT review?" asks the Dartmouth neuroscientist Michael Gazzaniga. "It's six of one and a half dozen of the other. If both can boost SAT scores by, say, 120 points, I think it's immaterial which way it's done."
This objection rests on the same false dichotomy as the first. As the University of Virginia's Moreno puts it, "We don't stop people from giving their kids tennis lessons." If anything, the new enhancements might increase social equality. Moreno notes that neuropharmaceuticals are likely to be more equitably distributed than genetic enhancements, because "after all, a pill is easier to deliver than DNA."
This is a flagrant example of the zero-sum approach that afflicts so much bioethical thought. Let's assume, for the sake of argument, that everyone in society will take a beneficial brain-enhancing drug. Their relative positions may not change, but the overall productivity and wealth of society would increase considerably, making everyone better off. Surely that is a social good.
For one thing, this misunderstands the nature of the technology. It's not simply a matter of popping a pill and suddenly zooming ahead. "I know a lot of smart people who don't amount to a row of beans," says Gazzaniga. "They're just happy underachieving, living life below their potential. So a pill that pumps up your intellectual processing power won't necessarily give you the drive and ambition to use it."
Beyond that, it's not as though we don't all face competitive pressures anyway -- to get into and graduate from good universities, to constantly upgrade skills, to buy better computers and more productive software, whatever. Some people choose to enhance themselves by getting a Ph.D. in English; others are happy to stop their formal education after high school. It's not clear why a pill should be more irresistible than higher education, or why one should raise special ethical concerns while the other does not.
"By denying access to brain-enhancing drugs, people like Fukuyama are advocating an exaggerated stoicism," counters Moreno. "I don't see the benefit or advantage of that kind of tough love." Especially since there will still be many different ways to achieve things and many difficult challenges in life. Brain-enhancing drugs might ease some of our labors, but as Moreno notes, "there are still lots of hills to climb, and they are pretty steep." Cars, computers, and washing machines have tremendously enhanced our ability to deal with formerly formidable tasks. That doesn't mean life's struggles have disappeared -- just that we can now tackle the next ones.
Help Reason celebrate its next 40 years. Donate Now!
Try Reason's award-winning print edition today! Your first issue is FREE if you are not completely satisfied.
Site comments/questions:
Media Inquiries and Reprint Permissions:
(310) 367-6109
Editorial & Production Offices:
3415 S. Sepulveda Blvd.
Suite 400
Los Angeles, CA 90034
(310) 391-2245